These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 16280454)
1. Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards. Zhang D; Zhang H; Aranibar N; Hanson R; Huang Y; Cheng PT; Wu S; Bonacorsi S; Zhu M; Swaminathan A; Humphreys WG Drug Metab Dispos; 2006 Feb; 34(2):267-80. PubMed ID: 16280454 [TBL] [Abstract][Full Text] [Related]
2. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777 [TBL] [Abstract][Full Text] [Related]
3. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection. Wang L; Zhang D; Swaminathan A; Xue Y; Cheng PT; Wu S; Mosqueda-Garcia R; Aurang C; Everett DW; Humphreys WG Drug Metab Dispos; 2006 Mar; 34(3):427-39. PubMed ID: 16381667 [TBL] [Abstract][Full Text] [Related]
4. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites. Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134 [TBL] [Abstract][Full Text] [Related]
5. Metabolism and disposition of 14C-labeled peliglitazar in humans. Wang L; Munsick C; Chen S; Bonacorsi S; Cheng PT; Humphreys WG; Zhang D Drug Metab Dispos; 2011 Feb; 39(2):228-38. PubMed ID: 20978103 [TBL] [Abstract][Full Text] [Related]
6. Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment. Zhang D; Raghavan N; Wang L; Xue Y; Obermeier M; Chen S; Tao S; Zhang H; Cheng PT; Li W; Ramanathan R; Yang Z; Humphreys WG Drug Metab Dispos; 2011 Jan; 39(1):123-31. PubMed ID: 20876787 [TBL] [Abstract][Full Text] [Related]
7. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469 [TBL] [Abstract][Full Text] [Related]
9. A 96-well single-pot liquid-liquid extraction, hydrophilic interaction liquid chromatography-mass spectrometry method for the determination of muraglitazar in human plasma. Xue YJ; Liu J; Unger S J Pharm Biomed Anal; 2006 Jun; 41(3):979-88. PubMed ID: 16533587 [TBL] [Abstract][Full Text] [Related]
10. Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology. Yao M; Swaminathan A; Srinivas N Biopharm Drug Dispos; 2007 Jan; 28(1):35-42. PubMed ID: 17117455 [TBL] [Abstract][Full Text] [Related]
11. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites. Prakash C; Cui D Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030 [TBL] [Abstract][Full Text] [Related]
12. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy. Colizza K; Awad M; Kamel A Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832 [TBL] [Abstract][Full Text] [Related]
13. Mass defect filtering on high resolution LC/MS data as a methodology for detecting metabolites with unpredictable structures: identification of oxazole-ring opened metabolites of muraglitazar. Zhang D; Cheng PT; Zhang H Drug Metab Lett; 2007 Dec; 1(4):287-92. PubMed ID: 19356057 [TBL] [Abstract][Full Text] [Related]
14. Optimization to eliminate the interference of migration isomers for measuring 1-O-beta-acyl glucuronide without extensive chromatographic separation. Xue YJ; Akinsanya JB; Raghavan N; Zhang D Rapid Commun Mass Spectrom; 2008; 22(2):109-20. PubMed ID: 18059002 [TBL] [Abstract][Full Text] [Related]
15. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Balani SK; Xu X; Pratha V; Koss MA; Amin RD; Dufresne C; Miller RR; Arison BH; Doss GA; Chiba M; Freeman A; Holland SD; Schwartz JI; Lasseter KC; Gertz BJ; Isenberg JI; Rogers JD; Lin JH; Baillie TA Drug Metab Dispos; 1997 Nov; 25(11):1282-7. PubMed ID: 9351905 [TBL] [Abstract][Full Text] [Related]
16. Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma. Yao M; Srinivas N Biomed Chromatogr; 2006 Oct; 20(10):1017-23. PubMed ID: 16506266 [TBL] [Abstract][Full Text] [Related]
17. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631 [TBL] [Abstract][Full Text] [Related]
18. A 96-well single-pot protein precipitation, liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of muraglitazar, a novel diabetes drug, in human plasma. Xue YJ; Liu J; Pursley J; Unger S J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):213-22. PubMed ID: 16388995 [TBL] [Abstract][Full Text] [Related]
19. Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans. Dow J; Piriou F; Wolf E; Dulery BD; Haegele KD Drug Metab Dispos; 1994; 22(5):738-49. PubMed ID: 7835226 [TBL] [Abstract][Full Text] [Related]
20. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]